INT111545

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.76
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 50
Total Number 50
Disease Relevance 22.19
Pain Relevance 5.88

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (VEGFA) growth (VEGFA) extracellular region (VEGFA)
proteinaceous extracellular matrix (VEGFA) cytoplasm (VEGFA)
Anatomy Link Frequency
endothelial cells 2
HT-1080 2
tube 1
SH-SY5Y 1
retina 1
VEGFA (Homo sapiens)
Pain Link Frequency Relevance Heat
metalloproteinase 124 100.00 Very High Very High Very High
cytokine 38 100.00 Very High Very High Very High
cINOD 61 99.82 Very High Very High Very High
Opioid 39 98.84 Very High Very High Very High
Morphine 34 97.96 Very High Very High Very High
agonist 19 96.48 Very High Very High Very High
antagonist 72 95.80 Very High Very High Very High
rheumatoid arthritis 77 94.96 High High
Potency 22 93.64 High High
imagery 57 92.32 High High
Disease Link Frequency Relevance Heat
Apoptosis 318 100.00 Very High Very High Very High
Lung Cancer 30 100.00 Very High Very High Very High
Myeloid Leukemia 29 99.84 Very High Very High Very High
Diabetes Mellitus 289 99.72 Very High Very High Very High
INFLAMMATION 109 99.72 Very High Very High Very High
Death 72 99.48 Very High Very High Very High
Sarcoma 7 99.12 Very High Very High Very High
Hypoxia 82 98.46 Very High Very High Very High
Injury 20 98.36 Very High Very High Very High
Fibromyalgia 4 98.04 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
MNTX inhibited MS, DAMGO and VEGF induced tyrosine phosphorylation (transactivation) of VEGF receptors 1 and 2.
Phosphorylation (phosphorylation) of VEGF
1) Confidence 0.76 Published 2006 Journal Microvasc. Res. Section Abstract Doc Link 16820176 Disease Relevance 0.06 Pain Relevance 0.67
Taken together, these results indicate that MNTX inhibits opioid-induced EC proliferation and migration via inhibition of VEGF receptor phosphorylation/transactivation with subsequent inhibition of RhoA activation.
Phosphorylation (phosphorylation/transactivation) of VEGF associated with opioid
2) Confidence 0.75 Published 2006 Journal Microvasc. Res. Section Abstract Doc Link 16820176 Disease Relevance 0 Pain Relevance 0.53
Protein expression was determined using antibodies against VEGF (Santa Cruz Biotechnologies, Santa Cruz, CA), P13K, phospho-AKT, AKT (Cell Signaling Technology, Danvers, MA) and ?
Phosphorylation (phospho) of VEGF
3) Confidence 0.70 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2925949 Disease Relevance 0 Pain Relevance 0
Importantly, capsiate suppressed VEGF-induced activation of Src kinase and phosphorylation of its downstream substrates, such as p125(FAK) and VE-cadherin, without affecting autophosphorylation of the VEGF receptor KDR/Flk-1.
Phosphorylation (autophosphorylation) of VEGF
4) Confidence 0.63 Published 2008 Journal Cancer Res. Section Abstract Doc Link 18172315 Disease Relevance 0 Pain Relevance 0.14
Endostatin also interacts with VEGF signal transduction by reducing VEGF-induced kinase (Erk1/2) phosphorylation [25].
Phosphorylation (phosphorylation) of VEGF-induced
5) Confidence 0.63 Published 2008 Journal J Orthop Surg Section Body Doc Link PMC2397381 Disease Relevance 0.17 Pain Relevance 0.16
VEGF165b fails to phosphorylate the VEGF-R2 intracellular tyrosine residues that mediate the angiogenic response (15).
Phosphorylation (phosphorylate) of VEGF
6) Confidence 0.62 Published 2010 Journal American Journal of Physiology - Lung Cellular and Molecular Physiology Section Body Doc Link PMC2886605 Disease Relevance 0.20 Pain Relevance 0
VEGF165b binds to VEGF-R2 with equal affinity to VEGF165, but it also phosphorylates VEGF-R2 but in a qualitatively unique way (15).
Phosphorylation (phosphorylates) of VEGF
7) Confidence 0.62 Published 2010 Journal American Journal of Physiology - Lung Cellular and Molecular Physiology Section Body Doc Link PMC2886605 Disease Relevance 0.18 Pain Relevance 0
However, it stimulates a unique pattern of VEGF-R2 tyrosine residue phosphorylation, contrasting with those activated by conventional isoforms (12).
Phosphorylation (phosphorylation) of VEGF
8) Confidence 0.61 Published 2010 Journal American Journal of Physiology - Lung Cellular and Molecular Physiology Section Body Doc Link PMC2886605 Disease Relevance 0 Pain Relevance 0.03
However, it stimulates a unique pattern of VEGF-R2 tyrosine residue phosphorylation, contrasting with those activated by conventional isoforms (12).
Phosphorylation (phosphorylation) of VEGF
9) Confidence 0.61 Published 2010 Journal American Journal of Physiology - Lung Cellular and Molecular Physiology Section Body Doc Link PMC2886605 Disease Relevance 0.18 Pain Relevance 0.03
Vatalanib decreased VEGF levels and VEGFR phosphorylation in AML cells, which showed FLT3 internal tandem reduplications/mutations (ITD), raising the question of the actual targeted tyrosine kinase (VEGFR or flt3).
Phosphorylation (phosphorylation) of VEGF in internal associated with myeloid leukemia
10) Confidence 0.61 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 1.71 Pain Relevance 0
MNTX inhibited MS, DAMGO and VEGF induced tyrosine phosphorylation (transactivation) of VEGF receptors 1 and 2.
Phosphorylation (phosphorylation) of VEGF
11) Confidence 0.58 Published 2006 Journal Microvasc. Res. Section Abstract Doc Link 16820176 Disease Relevance 0.06 Pain Relevance 0.67
A PI3K inhibitor LY294002 significantly suppressed AKT phosphorylation and VEGF expression, which is similar to PO treatment, implying that PI3K is related to and downstream of VEGF in the cells.
Phosphorylation (phosphorylation) of VEGF
12) Confidence 0.54 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2925949 Disease Relevance 0.28 Pain Relevance 0
The treatment with PO at 12.5 µg/ml reduced the levels of phosphorylated AKT and VEGF expression (intracellular and extracelluar) in HT-1080 cells.
Phosphorylation (phosphorylated) of VEGF in HT-1080
13) Confidence 0.54 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2925949 Disease Relevance 0.32 Pain Relevance 0.05
As expected, LY294002 significantly suppressed AKT phosphorylation and VEGF expression similar to PO treatment (Fig. 5D).
Phosphorylation (phosphorylation) of VEGF
14) Confidence 0.54 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2925949 Disease Relevance 0.12 Pain Relevance 0
Functional receptor binding studies by this group confirmed high levels of VEGF-VEGFR interaction only in Capan-1 cells; VEGF dose-dependently enhanced proliferation, promoted MAPK phosphorylation, and induced c-fos activity only in these Capan-1 cells [82].
Phosphorylation (phosphorylation) of VEGF in Capan-1
15) Confidence 0.54 Published 2003 Journal Mol Cancer Section Body Doc Link PMC150383 Disease Relevance 0.64 Pain Relevance 0.08
We did not show phosphorylation of VEGF-R2 in this study, because SW1990 expressed no VEGFR-2 mRNA.
Phosphorylation (phosphorylation) of VEGF
16) Confidence 0.48 Published 2010 Journal J Exp Clin Cancer Res Section Body Doc Link PMC2893453 Disease Relevance 0.68 Pain Relevance 0.16
Interestingly, we have observed significant decrease of VEGF-A production and VEGF-R1 phosphorylation by si-SW1990 and si-BxPC3 compared to parental cells.
Phosphorylation (phosphorylation) of VEGF-R1
17) Confidence 0.47 Published 2010 Journal J Exp Clin Cancer Res Section Body Doc Link PMC2893453 Disease Relevance 0.97 Pain Relevance 0.14
Interestingly, we have observed significant decrease of VEGF-A production and VEGF-R1 phosphorylation by si-SW1990 and si-BxPC3 compared to parental cells.
Phosphorylation (phosphorylation) of VEGF
18) Confidence 0.47 Published 2010 Journal J Exp Clin Cancer Res Section Body Doc Link PMC2893453 Disease Relevance 1.03 Pain Relevance 0.14
This study extends these finding by demonstrating that the potent protein tyrosine phosphatase inhibitor, 3,4-Dephostatin, blocks MNTX inhibition of VEGF-induced Src and Akt phosphorylation. 3,4-Dephostatin is known to block the phosphatase activity of PTP-1B, SHPTP-1 and CD45 [20,40,46-48].
Phosphorylation (phosphorylation) of VEGF-induced
19) Confidence 0.45 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2831839 Disease Relevance 0.21 Pain Relevance 0
Further, silencing mTOR blocked VEGF-induced serine, but not threonine Akt phosphorylation.
Phosphorylation (phosphorylation) of VEGF-induced
20) Confidence 0.45 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2831839 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox